Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each dropping 1.1%.
The iShares Biotechnology ETF (IBB) slipped 0.8%.
In corporate news, Eli Lilly's (LLY) weight loss drug Mounjaro will be rolled out initially to people with the highest clinical need in England over the next three years, according to the National Institute for Health and Care Excellence's draft guidance. Eli Lilly shares shed 0.5%.
Eli Lilly, Pfizer (PFE) and Pharmaceutical Research and Manufacturers of America executives dined with US President-elect Donald Trump on Wednesday night and held various discussions including potential public-private collaborations to find cures for cancer, Axios reported. Pfizer shares popped 2.2%.
Protara Therapeutics (TARA) shares surged past 75%. The company said its investigational therapy TARA-002 showed a complete response rate of 72% at six months in a phase 2 trial involving people with non-muscle invasive bladder cancer.
Novo Nordisk (NVO) said Thursday it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026. Its shares were 0.1% higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。